Edition:
India

People: AtriCure Inc (ATRC.OQ)

ATRC.OQ on NASDAQ Stock Exchange Global Market

27.30USD
22 Apr 2019
Change (% chg)

-- (--)
Prev Close
$27.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
83,638
52-wk High
$36.08
52-wk Low
$19.77

Privitera, Salvatore 

Mr. Salvatore Privitera serves as Chief Technology Officer of AtriCure Inc. since July 2017. Prior to joining AtriCure, Mr. Privitera served as Vice President of Research and Development at Bard Medical (“BMD”), a division of C.R. Bard, where he helped grow BMD approximately 40% in 5 years to over $1 billion in global revenue. He was responsible for a broad range of clinical platforms including Therapeutic Hypothermia, Urologic Drainage, Endourology, Brachytherapy, and Home Care where they impacted over 150 million patients on an annual basis. Prior to his role at BMD, Mr. Privitera worked for AtriCure as the Vice President of Engineering and Product Development for ten years. During his tenure at AtriCure, the company grew from a small startup into a public company, and he led development of many platform technologies including the AtriClip product line and the PMA approved Isolator® Synergy™ Ablation System. Prior to AtriCure, Mr. Privitera worked at Ethicon Endo-Surgery, a Johnson and Johnson company, in a variety of research, development and operations roles for over thirteen years. Mr. Privitera received his B.S. from the University of Buffalo, his M.B.A. from Xavier University and his J.D. from Northern Kentucky University.

Basic Compensation

Total Annual Compensation, USD 209,481
Restricted Stock Award, USD 1,414,800
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 1,624,280

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Scott Drake

194,982

Michael Carrel

4,156,350

M. Andrew Wade

1,075,720

Douglas Seith

1,841,050

Justin Noznesky

1,023,000

Salvatore Privitera

1,624,280
As Of  31 Dec 2017